12/22/2025 07:44
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishi...

12/22/2025 07:30
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusivel...

01/26/2026 22:00
FlightSafety International Receives FAA Approval for Gulfstream G700 Full Flight Simulator in Singapore

FlightSafety International Inc. (FSI), a global leader in aviation training and simulation technology, today announced the Federal Aviation Administration (FAA) has approved FlightSafety’s new Gulfstream G700 Level D Full Flight Simulator (FFS), located at the company’s Singapore Learning Center. The approval expands access to G700 training to the Asia-Pacific region. Gulfstream G700 training is now in operation at the Singapore Learning Center, joining existing training programs in Farnborou...

01/26/2026 23:14
The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Most Extravagant Date Night, Romantic Paint ‘n Pour Classes, ‘Sleepless in Seattle’ Screenings, Proposal Package, and More

Love is in the air at the “World’s Most Romantic Building.” The Empire State Building (ESB) today announced its romantic Valentine’s Day plans for couples in NYC, which include an over-the-top date night, Paint ‘n Pour classes, romantic movie screenings, a sunrise experience, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126953627/en/The World’s Most Romantic Building: ESB Celebrates Valentine’s Day 2026 with NYC's Mos...

01/26/2026 23:15
MSCI to Consult on a Potential Reclassification of Greece to Developed Market status

MSCI Inc. (NYSE: MSCI) announced today the launch of a consultation on a proposal for the potential reclassification of Greece from Emerging Market status to Developed Market status in one step, with implementation targeted for the August 2026 Index Review. As part of the MSCI 2025 Market Classification Review, MSCI acknowledged that the Greek market made progress in aligning with the accessibility standards commonly observed in Developed Markets in Europe and that Greece also meets the Econo...

01/27/2026 00:17
ANTA Sports to Acquire 29% Stake in PUMA, Further Strengthening Globalization Strategy

ANTA Sports Products Limited (“ANTA Sports” or the “Company,” stock codes: 2020 (HKD counter) and 82020 (RMB counter), and its subsidiaries collectively the “Group”), today announced it has reached a share purchase agreement with Groupe Artémis, the investment company of the Pinault family, to acquire a 29.06% stake in PUMA SE, the company behind iconic global sports brand PUMA. The stake is valued at EUR 1.5 billion in cash. The transaction marks a significant step in ANTA Sports’ globalizatio...

01/27/2026 01:00
Access Advance Extends HEVC Advance Rate Increase Deadline

Access Advance LLC today announced that the Licensors of HEVC Advance have approved an extension of the deadline for new Licensees to secure current royalty rates and caps through 2030. Companies that become Licensees of the HEVC Advance program on or before June 30, 2026 will secure current royalty rates for both ongoing royalties and calculation of royalties for past sales. This is a temporary postponement of the 25% increase in rates and caps applicable to Licensees who sign up after the p...

12/22/2025 08:00
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shangha...

Validation

Validation

Thanks! 

Your message has been sent.

Our teams will come back to you under best delay.